A Chioato

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Bioequivalence of canakinumab liquid pre-filled syringe and reconstituted lyophilized formulations following 150 mg subcutaneous administration: a randomized study in healthy subjects
    Andrea Chioato
    Novartis Institutes for BioMedical Research, Translational Medicine, 4002, Basel, Switzerland
    Clin Drug Investig 33:801-8. 2013
  2. pmc Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study
    A Chioato
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Clin Vaccine Immunol 19:1597-602. 2012
  3. pmc Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study
    A Chioato
    Novartis Institutes for BioMedical Research, Translational Science, CH 4002 Basel, Switzerland
    Clin Vaccine Immunol 17:1952-7. 2010

Collaborators

Detail Information

Publications3

  1. ncbi Bioequivalence of canakinumab liquid pre-filled syringe and reconstituted lyophilized formulations following 150 mg subcutaneous administration: a randomized study in healthy subjects
    Andrea Chioato
    Novartis Institutes for BioMedical Research, Translational Medicine, 4002, Basel, Switzerland
    Clin Drug Investig 33:801-8. 2013
    ..A new formulation (solution for injection as pre-filled syringe) has been developed to avoid reconstitution...
  2. pmc Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study
    A Chioato
    Novartis Institutes for BioMedical Research, Basel, Switzerland
    Clin Vaccine Immunol 19:1597-602. 2012
    ..A protective (≥4-fold) immune response to both vaccinations at 4 weeks was achieved in 80 and 76% of subjects exposed to secukinumab and the control, respectively...
  3. pmc Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study
    A Chioato
    Novartis Institutes for BioMedical Research, Translational Science, CH 4002 Basel, Switzerland
    Clin Vaccine Immunol 17:1952-7. 2010
    ..We concluded that a single dose of 300 mg canakinumab s.c. does not affect the induction or persistence of antibody responses after vaccination with unadjuvanted influenza or alum-adjuvanted MenC vaccines in healthy subjects...